Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

  • days left to enroll
  • participants needed
  • sponsor
    Peking University People's Hospital
Updated on 23 January 2021
graft versus host disease
acute leukemia
residual disease
induction chemotherapy
minimal residual disease
donor lymphocyte infusion
chronic graft versus host disease


Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse. Previous studies from investigators reported an association between a positive minimal residual disease (MRD)-test after transplant and an increased risk of subsequent relapse. Also, patients developing chronic graft-versus-host disease (GvHD) after receiving DLI (donor lymphocyte infusion)for leukemia relapse after a first allotransplant have a lower likelihood of a second relapse compared with similar patients not developing chronic GvHD. And, our previous study also reported patients with chronic GvHD after DLI was associated with a greater frequency of a negative MRD-test and lower likelihood of subsequent relapse compared with similar persons not developing chronic GvHD. Based on these data the investigators designed a randomized control study to determine whether giving additional consolidation chemotherapy and DLI might decrease likelihood of second relapse in persons without chronic GvHD or with a positive MRD-test after initial post-relapse therapy with induction chemotherapy and DLI.

Condition Minimal Residual Disease, Relapse, Graft-Versus-Host Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Recurrent Disease, Acute Leukemia, Donor Lymphocyte Infusion, Graft-Versus-Host Disease (GVHD), Allogeneic Hematopoietic Cell Transplantation, graft versus host disease, graft-versus-host-disease, relapsed disease, acute leukemias
Treatment Donor Lymphocyte Infusion
Clinical Study IdentifierNCT03297528
SponsorPeking University People's Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

(1) acute leukemia in first complete or second complete remission
(2) relapse after an allotransplant
(3) had full or partial donor chimerism
(4) received re-induction chemotherapy and DLI and achieved a negative MRD-test

Exclusion Criteria

(1) active GvHD
(2) active infection
(3) organ dysfunction
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note